{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T07:25:37Z","timestamp":1764573937212,"version":"3.46.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,30]]},"DOI":"10.7759\/cureus.98204","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T07:22:42Z","timestamp":1764573762000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Dynamics as a Complementary Marker of Treatment Response in Newly Diagnosed Multiple Myeloma: A Prospective Analysis"],"prefix":"10.7759","author":[{"given":"Veysel","family":"Erol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esin","family":"Avci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Kabukcu Hacioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nil","family":"Guler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsum","family":"Akgun Cagliyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ba\u015fak","family":"\u00dcnver Koluman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail Can","family":"Kendir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozde","family":"Elver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayihan","family":"Kara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhan","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevin","family":"Alayvaz Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo A","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011, 364:1046-60. 10.1056\/NEJMra1011442","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou L","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, et al.. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021, 21:606. 10.1186\/s12885-021-08280-y","journal-title":"BMC Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle RA","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002, 346:564-9. 10.1056\/NEJMoa01133202","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0030-3","article-title":"Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance","volume":"32","author":"Lakshman A","year":"2018","unstructured":"Lakshman A, Paul S, Rajkumar SV, et al.. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 2018, 32:1811-5. 10.1038\/s41375-018-0030-3","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle RA","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, et al.. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007, 356:2582-90. 10.1056\/NEJMoa070389","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima D","year":"2022","unstructured":"Dima D, Jiang D, Singh DJ, et al.. Multiple myeloma therapy: emerging trends and challenges. Cancers (Basel). 2022, 14:10.3390\/cancers14174082","journal-title":"Cancers (Basel)"},{"key":"ref7","article-title":"National Cancer Institute: SEER Cancer Statistics Review (CSR) 1975-2016","year":"2019","unstructured":"SEER Cancer Statistics Review (CSR) 1975-2016. Howlader N, Noone AM, Krapcho M, et al. (ed). National Cancer Institute, Bethesda, MD; 2019. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2016\/index.html."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab AK","year":"2012","unstructured":"Azab AK, Hu J, Quang P, et al.. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012, 119:5782-94. 10.1182\/blood-2011-09-380410","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro AM","year":"2013","unstructured":"Roccaro AM, Sacco A, Maiso P, et al.. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013, 123:1542-55. 10.1172\/JCI66517","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V87.8.3375.bloodjournal8783375","article-title":"Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells","volume":"87","author":"Tsujimoto T","year":"1996","unstructured":"Tsujimoto T, Lisukov IA, Huang N, Mahmoud MS, Kawano MM. Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. Blood. 1996, 87:3375-83.","journal-title":"Blood"},{"key":"ref11","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","author":"Yaccoby S","year":"2006","unstructured":"Yaccoby S, Wezeman MJ, Zangari M, et al.. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006, 91:192-9.","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.02.021","article-title":"Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast","volume":"75","author":"Reagan MR","year":"2015","unstructured":"Reagan MR, Liaw L, Rosen CJ, Ghobrial IM. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone. 2015, 75:161-9. 10.1016\/j.bone.2015.02.021","journal-title":"Bone"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani N","year":"2002","unstructured":"Giuliani N, Colla S, Sala R, et al.. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 2002, 100:4615-21. 10.1182\/blood-2002-04-1121","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos E","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, et al.. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003, 102:1064-9. 10.1182\/blood-2003-02-0380","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation","volume":"26","author":"Giuliani N","year":"2012","unstructured":"Giuliani N, Ferretti M, Bolzoni M, et al.. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia. 2012, 26:1391-401. 10.1038\/leu.2011.381","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.112","article-title":"PKA\/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells","volume":"28","author":"Medina EA","year":"2014","unstructured":"Medina EA, Oberheu K, Polusani SR, Ortega V, Velagaleti GV, Oyajobi BO. PKA\/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells. Leukemia. 2014, 28:2080-9. 10.1038\/leu.2014.112","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.63","article-title":"Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma","volume":"49","author":"Greenfield DM","year":"2014","unstructured":"Greenfield DM, Boland E, Ezaydi Y, Ross RJ, Ahmedzai SH, Snowden JA. Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. Bone Marrow Transplant. 2014, 49:907-12. 10.1038\/bmt.2014.63","journal-title":"Bone Marrow Transplant"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells","volume":"100","author":"Standal T","year":"2002","unstructured":"Standal T, Seidel C, Hjertner \u00d8, et al.. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002, 100:3002-7. 10.1182\/blood-2002-04-1190","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10613","article-title":"Activin A stimulates IkappaB-alpha\/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors","volume":"90","author":"Sugatani T","year":"2003","unstructured":"Sugatani T, Alvarez UM, Hruska KA. Activin A stimulates IkappaB-alpha\/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem. 2003, 90:59-67. 10.1002\/jcb.10613","journal-title":"J Cell Biochem"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.02.009","article-title":"The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance","volume":"21","author":"Lee C","year":"2015","unstructured":"Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015, 21:443-54. 10.1016\/j.cmet.2015.02.009","journal-title":"Cell Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03885-2","article-title":"Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging","volume":"21","author":"Wan W","year":"2023","unstructured":"Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023, 21:36. 10.1186\/s12967-023-03885-2","journal-title":"J Transl Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00331","article-title":"Mitochondrial-derived peptides are down regulated in diabetes subjects","volume":"10","author":"Ramanjaneya M","year":"2019","unstructured":"Ramanjaneya M, Bettahi I, Jerobin J, et al.. Mitochondrial-derived peptides are down regulated in diabetes subjects. Front Endocrinol (Lausanne). 2019, 10:331. 10.3389\/fendo.2019.00331","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13010125","article-title":"MOTS-c functionally prevents metabolic disorders","volume":"13","author":"Gao Y","year":"2023","unstructured":"Gao Y, Wei X, Wei P, et al.. MOTS-c functionally prevents metabolic disorders. Metabolites. 2023, 13:125. 10.3390\/metabo13010125","journal-title":"Metabolites"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.21917","article-title":"Osteoblast differentiation is functionally associated with decreased AMP kinase activity","volume":"221","author":"Kasai T","year":"2009","unstructured":"Kasai T, Bandow K, Suzuki H, et al.. Osteoblast differentiation is functionally associated with decreased AMP kinase activity. J Cell Physiol. 2009, 221:740-9. 10.1002\/jcp.21917","journal-title":"J Cell Physiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201811_16247","article-title":"MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-\u03b2\/Smad pathway","volume":"22","author":"Hu BT","year":"2018","unstructured":"Hu BT, Chen WZ. MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-\u03b2\/Smad pathway. Eur Rev Med Pharmacol Sci. 2018, 22:7156-63. 10.26355\/eurrev_201811_16247","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2024048","article-title":"MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis","volume":"56","author":"Yang L","year":"2024","unstructured":"Yang L, Li M, Liu Y, et al.. MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis. Acta Biochim Biophys Sin (Shanghai). 2024, 56:1323-39. 10.3724\/abbs.2024048","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp PR","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al.. International staging system for multiple myeloma. J Clin Oncol. 2005, 23:3412-20. 10.1200\/JCO.2005.04.242","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo A","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al.. Revised International Staging System for for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015, 33:2863-9. 10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino M","year":"2022","unstructured":"D'Agostino M, Cairns DA, Lahuerta JJ, et al.. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022, 40:3406-18. 10.1200\/JCO.21.02614","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13897","article-title":"Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: a real-world analysis","volume":"110","author":"Chen H","year":"2023","unstructured":"Chen H, Shi H, Zhou N, et al.. Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: a real-world analysis. Eur J Haematol. 2023, 110:229-35. 10.1111\/ejh.13897","journal-title":"Eur J Haematol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt TM","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021, 11:83. 10.1038\/s41408-021-00474-8","journal-title":"Blood Cancer J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19384","article-title":"Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation","volume":"204","author":"Alzahrani K","year":"2024","unstructured":"Alzahrani K, Pasvolsky O, Wang Z, et al.. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024, 204:1944-52. 10.1111\/bjh.19384","journal-title":"Br J Haematol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:e538-48. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey AS","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al.. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009, 150:604-12. 10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/424221-serum-mitochondrial-open-reading-frame-of-the-12s-rrna-c-mots-c-dynamics-as-a-complementary-marker-of-treatment-response-in-newly-diagnosed-multiple-myeloma-a-prospective-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T07:22:44Z","timestamp":1764573764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/424221-serum-mitochondrial-open-reading-frame-of-the-12s-rrna-c-mots-c-dynamics-as-a-complementary-marker-of-treatment-response-in-newly-diagnosed-multiple-myeloma-a-prospective-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.98204","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,30]]}}}